Xeris Biopharma Holdings (XERS) Change in Inventory (2020 - 2026)

Xeris Biopharma Holdings (XERS) has reported Change in Inventory for 7 consecutive years, with $9.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Inventory rose 25.47% year-over-year to $9.5 million; the trailing twelve-month figure through Jun 2026 stood at $16.7 million (up 8.92% YoY), and the FY2025 full-year result was $19.3 million, up 119.61% from the prior year.
• Change in Inventory advanced to $9.5 million in Q2 2026 per XERS's latest filing, from -$851000.0 in the prior quarter.
• Across five years, Change in Inventory topped out at $9.5 million in Q2 2026 and bottomed at -$851000.0 in Q1 2026.
• Historically, Change in Inventory has averaged $3.3 million across 5 years, with a median of $2.7 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Change in Inventory surged 4922.3% in 2023, then slumped 123.53% in 2026.
• Over 5 years, Change in Inventory stood at $5.5 million in 2022, then sank by 74.55% to $1.4 million in 2023, then jumped by 123.91% to $3.1 million in 2024, then rose by 27.86% to $4.0 million in 2025, then jumped by 136.9% to $9.5 million in 2026.
• According to Business Quant data, Change in Inventory over the past three periods registered $9.5 million, -$851000.0, and $4.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.